Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Cancers

Marketa Bednarikova¹  Lucie Ehrlichova¹  Vit Weinberger²  Eliska Gazarkova²  Lubos Minar²  Jitka Hausnerova³  Kvetoslava Matulova³ 

[1] Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, 625 00 Brno, Czech Republic;Department of Obstetrics and Gynecology, Masaryk University and University Hospital, 625 00 Brno, Czech Republic;Department of Pathology, Masaryk University and University Hospital, 625 00 Brno, Czech Republic;

关键词: SLFN11;    ovarian cancer;    high-grade serous carcinoma;    DNA-damaging agents;    PARPi;    chemoresistance;   

DOI  :  10.3390/cancers14102353

来源: DOAJ

【 摘 要 】

Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.

【 授权许可】

Unknown